Tag: Lord Clement-Jones

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-29.

To ask Her Majesty’s Government whether they support the proposal that NHS England will only pay for patients participating in data collection under the new NICE conditional approval route.

Lord Prior of Brampton

NHS England and the National Institute for Health and Care Excellence have proposed that, where a drug is recommended for use within the Cancer Drugs Fund (CDF), its entry into the Fund would be subject to the company agreeing to fund the collection of a pre-determined data set, during a period normally lasting no longer than 24 months, and a commercial access arrangement which is affordable within the available CDF budget.

Access by eligible patients will not be restricted to the number of patients considered necessary for data collection, but any costs for treatment over and above this number will be paid for by the company.

At its meeting on 25 February 2016, the NHS England Board agreed a way forward which will see the new operating model going live on 1 July 2016.

The Accelerated Access Review is looking at ways to better use data on treatments and outcomes from initiatives, such as the CDF, to drive innovation, adoption and reimbursement of novel treatments.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-29.

To ask Her Majesty’s Government what involvement the Prime Minister has had in the formation of proposals for a new Cancer Drugs Fund.

Lord Prior of Brampton

NHS England and the National Institute for Health and Care Excellence are developing the proposed new arrangements for the Cancer Drugs Fund. My Rt. hon. Friend the Secretary of State for Health, my hon. Friend the Minister for Life Sciences and the Prime Minister have been kept informed as this work has been progressed.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-29.

To ask Her Majesty’s Government what is the anticipated budget impact of the new Cancer Drugs Fund in 2016–17, 2017–18, 2019–20, and 2020–21.

Lord Prior of Brampton

NHS England has advised that it expects that the impact of the new Cancer Drugs Fund on the 2016–17 budget held within NHS England will be no more than £340 million.

For future years, NHS England’s aim is to contain the whole budget impact within £340 million over a longer time period, alongside a more structured and timely approach to the appraisal of all cancer drugs.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-29.

To ask Her Majesty’s Government what is the total budget that NHS England has allocated for the new Cancer Drugs Fund in 2016–17, 2017–18, 2019–20, and 2020–21.

Lord Prior of Brampton

NHS England has advised that it expects that the impact of the new Cancer Drugs Fund on the 2016–17 budget held within NHS England will be no more than £340 million.

For future years, NHS England’s aim is to contain the whole budget impact within £340 million over a longer time period, alongside a more structured and timely approach to the appraisal of all cancer drugs.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-22.

To ask Her Majesty’s Government how many cancer medicines launched since June 2015 are available via the Cancer Drugs Fund.

Lord Prior of Brampton

No new cancer medicines have been added to the national Cancer Drugs Fund (CDF) list since June 2015. As part of its work to reprioritise the Fund in 2015-16, NHS England took the decision not to consider new drugs for inclusion on the national CDF list.

NHS England and the National Institute for Health and Care Excellence (NICE) recently consulted on draft proposals for the future direction of the Fund. The consultation outlines a new system, fully integrated into the NICE appraisal process, where the CDF becomes a transitional fund – with clear criteria for entry and exit.

Clinicians continue to be able to apply for cancer drugs not on the national CDF list through the Individual Cancer Drugs Funding Request procedure.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-29.

To ask Her Majesty’s Government what plans the Department of Health has to instruct NICE to include a broader assessment of value in its appraisals of cancer medicines.

Lord Prior of Brampton

The National Institute for Health and Care Excellence (NICE) is the independent body that provides guidance on the prevention and treatment of ill health and the promotion of good health and social care. NICE is responsible for its own processes and methodology.

In 2014, NICE held a three month consultation on proposals for a wider approach to the assessment of value. The diversity of the responses to NICE’s consultation showed that this is a very complex issue. It is critical that stakeholders continue to have confidence in NICE’s work and the Government agreed with NICE that it should not proceed with making the proposed changes to the way it assesses new medicines at that time.

NICE regularly reviews its processes and methodology and its internationally renowned technology appraisal programme has evolved constantly to meet new challenges. NICE has demonstrated its ability to adapt to changes in the health and care environment, and we expect it will continue to evolve in the future.

NICE most recently consulted on proposed changes to its technology appraisal methods and processes as part of its joint consultation with NHS England on proposals for a new Cancer Drugs Fund (CDF).

The Accelerated Access Review (AAR) is actively engaging with NHS England to ensure alignment between the work of the review on speeding up access for NHS patients to innovative and cost effective new medicines and the CDF. The AAR is looking at the capability of NICE, NHS England and the Department to support innovative pathways for the assessment, adoption and reimbursement of treatments.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-22.

To ask Her Majesty’s Government whether they have had discussions with NHS England and the National Institute for Health and Care Excellence about whether new medicines not accessible through the Cancer Drugs Fund since June 2015 will be prioritised for early review under the proposed new terms of that Fund.

Lord Prior of Brampton

The Department has had regular discussions with the National Institute for Health and Care Excellence and NHS England about the future operation of the Cancer Drugs Fund, including arrangements for the assessment of cancer drugs that are not currently available through the Fund.

The below Parliamentary question was asked by Lord Clement-Jones on 2016-02-29.

To ask Her Majesty’s Government what assessment they have made of the effectiveness of the Systemic Anti-Cancer Therapy Dataset in the collection of health outcome data from patients receiving cancer medicines paid for by the Cancer Drugs Fund.

Lord Prior of Brampton

In July 2015, NHS England and Public Health England (PHE) signed a data sharing agreement concerning the Cancer Drugs Fund (CDF) use, enabling NHS England to provide to PHE details of patients for whom a CDF treatment had been requested by clinicians. This will enable PHE to link information on patients for whom a CDF treatment was requested (from 1 April 2013 onwards) with a range of other data sets.

There is presently no agreement between NHS England and PHE in terms of providing outcome information on patients receiving CDF funded treatments, or other systemic anti-cancer therapies, on a regular basis. However, PHE and NHS England are currently having detailed and productive discussions to establish a dedicated core resource which will provide NHS England with routine and bespoke information and analysis, focusing on both routine chemotherapy and activity data and outcome and quality metrics, which can include outcome analyses on the CDF.

The Accelerated Access Review is looking at ways to better use data on treatments and outcomes from initiatives, such as the CDF, to drive innovation, adoption and reimbursement of novel treatments.

The below Parliamentary question was asked by Lord Clement-Jones on 2014-06-04.

To ask Her Majesty’s Government whether they have issued guidance as to whether members of either House of Parliament are, or should be, considered as Politically Exposed Persons for the purposes of United Kingdom financial regulation; and, if so, what guidance.

Lord Deighton

The UK’s Money Laundering Regulations 2007 define Politically Exposed Persons [PEPs]. UK Members of Parliament are not currently considered PEPs for UK purposes. However, revised global standards require that they are treated as PEPs.

As similar definitions apply in other jurisdictions UK Parliamentarians are likely to be considered as PEPs in other jurisdictions. We are seeking a risk-based approach to the application of this requirement in negotiating the Fourth Money Laundering Directive.

Treasury Ministers have approved industry guidance which further confirms that UK Parliamentarians are not PEPs for UK purposes. Some UK banks may apply enhanced due diligence to UK Parliamentarians in accordance with their own risk appetite, and as part of global policies and procedures.